Stock Fundamentals

Company Information

Company Name
Roivant Sciences Ltd
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: BMG762791017
CIK: 0001635088
CUSIP: G76279101
Currency: USD
Full Time Employees: 721
Phone: 44 20 7400 3347
Fiscal Year End: March
IPO Date: Oct 01, 2021
Description:

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.

Address:

50 Broadway, London, United Kingdom, SW1H 0DB

Directors & Officers

Name Title Year Born
Mr. Matthew Gline CEO & Director 1984
Dr. Eric Venker M.D., Pharm.D. President & CEO of Immunovant 1987
Dr. Mayukh Sukhatme M.D. President, Chief Investment Officer & Director 1976
Mr. Richard Pulik Chief Financial Officer 1980
Ms. Jennifer Humes Chief Accounting Officer 1982
Dr. Frank M. Torti M.B.A., M.D. President & Vant Chair 1979
Dr. Huafeng Xu Ph.D. Chief Technology Officer NA
Mr. Ian Rosenblum Chief Information Officer NA
Mr. Josh Chen J.D. General Counsel NA
Ms. Kelly Graff Head of People NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 20, 2026 Eric Venker N/A Sale 200.00K $29.59 $5.92M
Apr 16, 2026 Matthew Gline N/A Sale 289.77K $29.16 $8.45M
Apr 08, 2026 Jennifer Humes N/A Sale 13.54K $28.37 $384.07K
Mar 17, 2026 Eric Venker N/A Sale 200.00K $28.24 $5.65M
Mar 16, 2026 Melissa B Epperly N/A Sale 41.86K $28.68 $1.20M
Feb 23, 2026 Frank Torti N/A Sale 587.39K $27.51 $16.16M
Feb 20, 2026 Frank Torti N/A Sale 1.01M $27.15 $27.49M
Feb 19, 2026 Frank Torti N/A Sale 1.40M $27.42 $38.39M
Feb 13, 2026 Daniel Allen Gold N/A Sale 375.78K $26.50 $9.96M
Feb 13, 2026 Eric Venker N/A Sale 200.00K $26.49 $5.30M
Feb 11, 2026 Daniel Allen Gold N/A Sale 425.00K $26.67 $11.33M
Feb 09, 2026 Mayukh Sukhatme N/A Sale 339.44K $26.47 $8.99M
Jan 12, 2026 Eric Venker N/A Sale 200.00K $21.92 $4.38M
Dec 31, 2025 Mayukh Sukhatme N/A Sale 1.02M $21.71 $22.12M
Dec 29, 2025 Mayukh Sukhatme N/A Sale 311.87K $21.74 $6.78M
Dec 24, 2025 Eric Venker N/A Sale 75.00K $22.53 $1.69M
Dec 23, 2025 Eric Venker N/A Sale 200.00K $22.45 $4.49M
Dec 23, 2025 Richard Pulik N/A Sale 406.73K $22.43 $9.12M
Dec 17, 2025 Daniel Allen Gold N/A Sale 777.33K $23.07 $17.93M
Dec 17, 2025 Mayukh Sukhatme N/A Sale 26.83K $23.09 $619.53K

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
FMR Inc 77.98M Mar 31, 2026 10.84% $0.11 18.55%
Morgan Stanley - Brokerage Accounts 51.83M Mar 31, 2026 7.21% $0.09 -11.19%
BlackRock Inc 44.25M Mar 31, 2026 6.15% $0.02 7.49%
Vanguard Group Inc 42.06M Dec 31, 2025 5.85% $0.01 8.39%
Qvt Financial LP 25.16M Mar 31, 2026 3.50% $51.04 -4.65%
UBS Group AG 22.62M Mar 31, 2026 3.14% $0.09 22.99%
Vanguard Capital Management, LLC 20.68M Mar 31, 2026 2.88% $0.01 0.00%
Vanguard Portfolio Management, LLC 19.84M Mar 31, 2026 2.76% $0.03 0.00%
State Street Corp 16.19M Mar 31, 2026 2.25% $0.02 -6.77%
Adage Capital Partners Gp LLC 12.79M Mar 31, 2026 1.78% $0.55 19.82%
The Goldman Sachs Group Inc 11.11M Mar 31, 2026 1.54% $0.04 1.17%
Geode Capital Management, LLC 10.18M Mar 31, 2026 1.42% $0.02 24.88%
Farallon Capital Management, L.L.C. 9.68M Mar 31, 2026 1.35% $1.53 26,048.65%
Two Seas Capital LP 9.33M Mar 31, 2026 1.30% $3.61 -4.73%
Perceptive Advisors LLC 8.29M Mar 31, 2026 1.15% $4.48 3.76%
Patient Square Capital LP 8.17M Mar 31, 2026 1.14% $40.13 0.00%
Dimensional Fund Advisors, Inc. 7.48M Mar 31, 2026 1.04% $0.04 -19.16%
Assenagon Asset Management SA 7.08M Mar 31, 2026 0.98% $0.30 2.01%
T. Rowe Price Associates, Inc. 6.99M Mar 31, 2026 0.97% $0.02 31.06%
Darwin Global Management, Ltd. 6.80M Mar 31, 2026 0.95% $4.76 0.00%

Shares Statistics

Shares Outstanding: 719.27M
Shares Float: 563.99M
% Insiders: 2,338.50%
% Institutions: 7,606.70%
Short % Float: 6.09%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Growth Compy Commingled Pl S 29.43M 4.09% ▲ 1.22% Apr 30, 2026
2 Fidelity Growth Company Fund 22.34M 3.11% ▲ 1.26% Apr 30, 2026
3 iShares Core S&P Mid-Cap ETF 15.30M 2.13% ▲ 0.02% May 29, 2026
4 Vanguard Total Stock Mkt Idx Inv 14.83M 2.06% ▲ 0.25% Apr 30, 2026
5 Vanguard Small Cap Index 10.72M 1.49% ▼ 0.19% Apr 30, 2026
6 Fidelity Growth Company K6 6.19M 0.86% ▲ 0.70% Apr 30, 2026
7 Vanguard Small Cap Growth Index Inv 6.01M 0.84% ▼ 0.05% Apr 30, 2026
8 Fidelity Series Growth Company 5.64M 0.78% ▼ 1.68% Apr 30, 2026
9 Morgan Stanley Inst Growth I 5.46M 0.76% ▼ 14.30% Mar 31, 2026
10 Morgan Stanley Growth 5.46M 0.76% ▼ 14.30% Mar 31, 2026

Valuation Metrics

Enterprise Value: $21.69B
Trailing P/E: 0.00
Forward P/E: 0.00

Financial Highlights

Market Cap: $25.87B
EBITDA: $-1.28B
Book Value: $6.29
Earnings/Share: $-0.54
Profit Margin: 0.00%
Operating Margin: -14,675.08%
ROA (TTM): -14.35%
ROE (TTM): -7.59%
Revenue (TTM): $8.26M
Revenue/Share (TTM): $0.01
Earnings Growth (YOY): -96.10%
Revenue Growth (YOY): -66.70%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2026-03-31 18.37x 0.00x 0.08x N/A -0.04x
2025-03-31 33.47x 0.00x 0.05x N/A -0.01x
2024-03-31 25.24x 0.08x 0.11x -23.72x 0.10x
2023-03-31 6.60x 0.37x 0.33x -28.93x -0.51x
2022-03-31 11.64x 0.13x 0.20x -172.10x -0.24x
2021-03-31 9.99x 0.10x 0.20x -381.24x -0.20x
2020-03-31 24.09x 0.00x 0.15x -69.30x -0.01x
2019-03-31 5.61x 0.02x 0.32x -99.32x 0.15x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ROIV.US!